how transformational is this change and what does it mean for glaxco? >> reporter: glaxco is breaking the hold. it will stop paying doctors to promote drugs. the producer of top selling medications and tums and aquafresh is also changing how it pays sells representatives. it will now tie composition to the number of prescriptions doctors write. the company says it's been a competitive advantage because health care professionals appreciate the chance petranspa. the ceo says it will bring greater clarity and confidence when we talk to a doctor, nurse or prescriber, it will be patient's interest. >> there are good reasons the industry used physicians as their advocates when it's connected with direct payment that's when you have conflict of interest. >> reporter: glaxco may be trying to repair it's reputation. in china it's accused of bribing hospitals, and officials and paid a 3 billion-dollar fine in the united states to settle acquisitions that marketed drugs for unapproved uses. in the past few years other drug companies like johnson & johnson, fazer a